We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
No fiscal-year history available for this company yet.
No P/E, the company is not profitable on a trailing basis.
Shenzhen Edge Medical Co., Ltd. engages in designing, developing, manufacturing, and sale of surgical robots in Europe, and China. The company focus on surgical robots and instruments for minimally invasive surgery or MIS, including multi-port endoscopic surgical robots and single-port endoscopic surgical robots. Its products include Edge Multi-Port Endoscopic Surgical Robot, a robot-assisted device that is applied to perform MIS using robotic, imaging, and digital technologies; Edge Single-Port Endoscopic Surgical Robot, a robot-assisted device that is applied to perform MIS through a single small incision or natural orifice; Edge Cloud Telesurgery System; and Edge Bronchoscope Robot. The company also develops and manufactures instruments for Edge Multi-Port Endoscopic Surgical Robot and Single-Port Endoscopic Surgical Robot includes bipolar grasping forceps, bipolar separation forceps, needle holder forceps, monopolar scissors, monopolar electric hooks and other surgical tools. In addition, the company develops an non-invasive surgery by developing natural orifice surgical robots. It serves hospitals. The company sells its products through distributors. The company was formerly known as Shenzhen Jingfeng Medical Technology Co., Ltd. The company was incorporated in 2017 and is based in Shenzhen, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 2675.HK and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
